The Need
Rapidly identify patients with suspected viral hemorrhagic fever- Ebola virus disease outbreaks continue to pose a significant global health threat requiring rapid identification and public health response.1,2
- Lassa fever is estimated to cause 100,000–300,000 infections and approximately 5,000 deaths annually in West Africa.3,4
- Marburg virus and Crimean-Congo hemorrhagic fever (CCHF) continue to cause outbreaks across multiple regions, with CCHF responsible for an estimated 10,000-15,000 human infections annually, highlighting the need for rapid detection and outbreak response.6-8
Support timely infection control and outbreak response- Early symptoms of Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever (CCHF) are often non-specific and difficult to distinguish from other febrile illnesses.1
- Rapid detection is critical to support patient isolation, infection prevention measures, and public health notification.1,2
1 CDC. Screening and Evaluating an Ill Person for Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/diagnosis-testing/index.html
2 CDC. Infection Prevention and Control for Patients with Suspected or Confirmed Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/index.html [ecdc.europa.eu]
3 WHO. Lassa Fever Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/lassa-fever [ijprems.com]
4 CDC. Lassa Fever Fact Sheet. https://stacks.cdc.gov/view/cdc/12236/cdc_12236_DS1.pdf [cdc.gov]
5 World Health Organization. Marburg virus disease - Equatorial Guinea and the United Republic of Tanzania. Disease Outbreak News, May 8, 2023. [who.int]
6 Centers for Disease Control and Prevention (CDC). History of Marburg Outbreaks. Updated 2025. [cdc.gov]
7 World Health Organization. Crimean-Congo hemorrhagic fever: Fact Sheet. Updated February 20, 2025. [who.int]
8 UK Health Security Agency. Crimean-Congo hemorrhagic fever: origins, reservoirs, transmission and guidelines. Updated 2025. [gov.uk]
The Solution
Xpert Hemorrhagic Fever Panel:- Simultaneously detects Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever viruses
- Produces results in approximately 70 minutes
- Closed-cartridge system minimizes contamination risk
- Sample processing includes viral inactivation to support safer handling9
- On-demand, random-access testing
- Supports fast clinical and infection control decisions
9. FDA 510(k) Decision Summary, Xpert® Hemorrhagic Fever Panel (K253653). Inactivation study results demonstrating viral inactivation during sample preparation are described in the submission documentation (see p. 23). Available at: https://www.accessdata.fda.gov/cdrh_docs/reviews/K253653.pdf.
The Impact
- Provide information that may support infection prevention protocols1,2
- Support communication with infection prevention teams and public health authorities1,2
- Reduce diagnostic uncertainty for patients with suspected viral hemorrhagic fever1
- Provide results in approximately 70 minutes to support outbreak response efforts1,2
1 CDC. Screening and Evaluating an Ill Person for Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/diagnosis-testing/index.html
2 CDC. Infection Prevention and Control for Patients with Suspected or Confirmed Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/index.html [ecdc.europa.eu]